冠状动脉无复流现象的当前认识  

Current understanding of no-reflow phenomenon

作　　者：李少辉[1] 王海昌[1] 张英梅[1] 

机构地区：[1]第四军医大学西京医院心血管内科,陕西西安710032

出　　处：《心脏杂志》2016年第2期226-230,共5页Chinese Heart Journal

摘　　要：经皮冠状动脉介入治疗(PCI)是急性ST段抬高性心肌梗死患者的首选治疗策略。虽然PCI后冠脉血流恢复,但仍经常观察到无复流现象,并且与较差的临床预后有关。导致该现象的病因机制复杂且相互关联,对这些机制的进一步认识有助于制定个性化的预防和治疗策略。可以使用冠脉造影、心肌对比超声及心脏磁共振等技术诊断无复流。许多药物可能改善实验室和临床无复流,但一些药物尚未明确地改善临床结果。Primary percutaneous coronary intervention （PC[） is the preferred treatment for ST segment elevation myocardial infarction. Although there is restoration of coronary flow after PCI, no-reflow phe- nornenon is frequently observed and may lead to poor prognosis. The pathogenic mechanisms that cause this phenomenon are complex and interrelated. A better understanding of these mechanisms could promote the development of individualized prevention and treatment strategies. Diagnosis of ＇ no-reflow＇ can be made using angioga＇aphy, myocardial contrast echocardiography or cardiovascular magnetic resonance. A number of drugs may improve no-reflow experimentally and clinically, but some have not yet been associated with conclusive improvements in clinical outcome.

关 键 词：无复流 经皮冠状动脉介入治疗 心肌梗死 再灌注 

分 类 号：R541.4[医药卫生—心血管疾病]